Bepirovirsen Breakthrough: Functional Cure for Chronic Hepatitis B

Here’s a list of the references, extracted from the provided text, formatted for easy citation:

1. Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) (B-Well 1).ClinicalTrials.gov identifier: NCT05630807. Updated December 12, 2025. Accessed January 8, 2026.https://clinicaltrials.gov/study/NCT05630807

2. Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) (B-Well 2). ClinicalTrials.gov identifier: NCT05630820. Updated December 12, 2025. Accessed January 8, 2026. https://clinicaltrials.gov/study/NCT05630820

3. Mayo Clinic Staff. Hepatitis B. News release.Mayo Clinic. December 9, 2025. Accessed January 8, 2026.https://www.mayoclinic.org/diseases-conditions/hepatitis-b/symptoms-causes/syc-20366802

4. Yuen M, Lim S, Plesniak R, et al. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection.N engl J Med 2022;387:1957-1968. doi:10.1056/NEJMoa2210027

5. A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB) (B-Clear). ClinicalTrials.gov identifier: NCT04449029. updated May 16, 2023. Accessed January 8, 2026. https://clinicaltrials.gov/study/NCT04449029